Austin Epstein
Medical · Staten Island, NYNPI 1245539949
Payments from drug & device makers
Across 581 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$2K
- Novo Nordisk$2K
- Lilly USA, LLC$814
- GSK$784
- Otsuka America Pharmaceutical, Inc.$706
- plus $5K from 42 others
What the payments were for
- Food & beverage$12,949100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$371
- Reltone 200 Mg$353
- GLYCATE$353
- Reltone 400 Mg$353
- RYBELSUS$328
- VRAYLAR$318
- REXULTI$244
- AIRSUPRA$234
- VERQUVO$203
- Kerendia$125
- NURTEC ODT$125
- NEXLIZET$125
- NEXLETOL$125
- FARXIGA$124
- Ozempic$114
- Austedo XR$111
How this compares
$12,949 in reported general payments places this provider in the 95th percentile of 2,395 medical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 45 | $52,227 |
| FarxigaDapagliflozin Propanediol | 24 | $32,642 |
| RexultiBrexpiprazole | 16 | $31,753 |
| OzempicSemaglutide | 21 | $31,689 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $16,946 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 120 | $15,054 |
| LinzessLinaclotide | 17 | $12,772 |
| QuviviqDaridorexant Hcl | 11 | $5,087 |
| EdluarZolpidem Tartrate | 12 | $4,973 |
| VascepaIcosapent Ethyl | 12 | $3,976 |
| DuleraMometasone/Formoterol | 12 | $3,940 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 55 | $1,671 |
| Levothyroxine Sodium | 53 | $1,417 |
| Oxycodone Hcl | 42 | $1,307 |
| Gabapentin | 124 | $1,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $814 | $52,22745 claims |
| AstraZenecaFarxiga | $1,676 | $32,64224 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $706 | $31,75316 claims |
| Novo NordiskOzempic | $1,525 | $31,68921 claims |
| GSKTrelegy Ellipta | $784 | $16,94620 claims |
| AbbVieLinzess | $2,143 | $12,77217 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $204 | $5,08711 claims |
| MerckDulera | $204 | $3,94012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,395 medical providers in New York.
Other medical in Staten Island
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
- Hailey BrickmanNew York$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.